Asset Details
Do you wish to reserve the book?
Dawn of CAR-T cell therapy in autoimmune diseases
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Dawn of CAR-T cell therapy in autoimmune diseases
Do you wish to request the book?
Dawn of CAR-T cell therapy in autoimmune diseases
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Dawn of CAR-T cell therapy in autoimmune diseases
2024
Overview
Abstract
Chimeric antigen receptor (CAR)-T cell therapy has achieved remarkable success in the treatment of hematological malignancies. Based on the immunomodulatory capability of CAR-T cells, efforts have turned toward exploring their potential in treating autoimmune diseases. Bibliometric analysis of 210 records from 128 academic journals published by 372 institutions in 40 countries/regions indicates a growing number of publications on CAR-T therapy for autoimmune diseases, covering a range of subtypes such as systemic lupus erythematosus, multiple sclerosis, among others. CAR-T therapy holds promise in mitigating several shortcomings, including the indiscriminate suppression of the immune system by traditional immunosuppressants, and non-sustaining therapeutic levels of monoclonal antibodies due to inherent pharmacokinetic constraints. By persisting and proliferating in vivo, CAR-T cells can offer a tailored and precise therapeutics. This paper reviewed preclinical experiments and clinical trials involving CAR-T and CAR-related therapies in various autoimmune diseases, incorporating innovations well-studied in the field of hematological tumors, aiming to explore a safe and effective therapeutic option for relapsed/refractory autoimmune diseases.
Publisher
Lippincott Williams & Wilkins,Lippincott Williams & Wilkins Ovid Technologies,Wolters Kluwer
Subject
/ Antigens
/ Autoimmune Diseases - immunology
/ Autoimmune Diseases - therapy
/ Cells
/ Disease
/ Humans
/ Immunotherapy, Adoptive - methods
/ Keywords
/ Leukemia
/ Lupus
/ Lupus Erythematosus, Systemic - immunology
/ Lupus Erythematosus, Systemic - therapy
/ Lymphoma
/ Multiple Sclerosis - immunology
/ Multiple Sclerosis - therapy
/ Receptors, Chimeric Antigen - immunology
/ Review
/ Tumors
